Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-27
    E.g., 2018-06-27

Articles

172427 items
12:00 AM, Jan 31, 1994  |  BC Week In Review | Company News  |  Other News

Liposome Tech, Vestar Inc. news

The decision will be appealed to the U.S. Court of Appeals for the Federal Circuit. LTIZ, which received the patent on Jan. 13, 1993, contends the patent covers all formulations of amphotericin B, while...
12:00 AM, Jan 31, 1994  |  BC Week In Review | Company News  |  Other News

Xoma Corp. other research news

XOMA (Berkeley) published findings on the 23-kilodalton rBPI protein showing that it contains three functional binding domains, pointing the way for additional clinical applications of the molecule. In the Journal of Biological Chemistry, the...
12:00 AM, Jan 31, 1994  |  BC Week In Review | Clinical News  |  Clinical Status

EPC-KI: Filed amendment to an IND

Chemex Pharmaceuticals Inc. (CHMX), Fort Lee, N.J.   Product: EPC-KI anti-inflammatory molecule combining vitamins C and E   Indication: Mild to moderate atopic dermatitis (allergic rash)   Status: Filed amendment to an IND to allow enrollment of...
12:00 AM, Jan 31, 1994  |  BC Week In Review | Company News  |  Deals

Disease Detection International Inc, Trinity Biotech deal

DOTS’ directors approved a merger proposal offered by HIVSY (Ireland) under which the remaining classes of DOTS stock will be exchanged for HIVSY’s American Depositary Receipts on a share-for-share basis. The merged company will have...
12:00 AM, Jan 31, 1994  |  BC Week In Review | Company News  |  Deals

American Biogenetic deal

MABXA (Notre Dame, Ind.) acquired several therapeutics to treat epilepsy from The National University of Ireland (Dublin). MABXA’s ABS Global Scientific Network, an entity where scientists from both parties can work together, will develop the...
12:00 AM, Jan 31, 1994  |  BC Week In Review | Clinical News  |  Clinical Status

Provir: Started a Phase II trial

Shaman Pharmaceuticals Inc. (SHMN), South San Francisco   Product: Provir, oral antiviral compound   Indication: Respiratory syncytial virus (RSV)   Status: Started a Phase II trial in hospitalized children, initially to evaluate pharmacokinetics and tolerance in 30 children...
12:00 AM, Jan 31, 1994  |  BC Week In Review | Company News  |  Deals

Oncotech deal

Oncotech (Irvine, Calif.) and the University of California at Irvine will develop ovarian cancer vaccines using genetically engineered cell lines discovered by UCI professor Gale Morrie Granger. Privately held Oncotech develops anticancer therapies and provides...
12:00 AM, Jan 31, 1994  |  BC Week In Review | Company News  |  Deals

DNA Plant Techonogy Corp. deal

DNAP (Cinnaminson, N.J.) completed its previously announced acquisition of DuPont’s ownership interest in the FreshWorld premium fruit and vegetable business that had been a 50-50 joint venture. DNAP acquired full ownership of FreshWorld in exchange...
12:00 AM, Jan 31, 1994  |  BC Week In Review | Company News  |  Sales & Marketing

PerSeptive sales and marketing update

PBIO (Cambridge, Mass.) introduced POROS Self Pack, a system used to pack Perfusion Chromatography columns. PBIO said the Self Pack system can reduce the $500-$1,000 price tag of high performance chromatography by 90 percent. PerSeptive...
12:00 AM, Jan 31, 1994  |  BC Week In Review | Company News  |  Deals

Future Medical Products Inc. deal

FMPI (Hauppauge, N.Y.) said its Devaron Inc. subsidiary entered into a five-year agreement with Healthcare Technologies Ltd.’s Savyon Diagnostic unit to manufacture and distribute rapid diagnostic kits for infectious diseases. Devaron will receive a $500,000...

Pages